Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine disorders, with its most significant political signal being $13.9M in 2024 doctor payments and a $1,001-$15,000 stock holding by Donald J. Trump.
BusinessWhat NBIX does
Neurocrine Biosciences develops and commercializes pharmaceuticals for neurological, psychiatric, and endocrine disorders. Its revenue is driven by products like Ingrezza for tardive dyskinesia and Ongentys for Parkinson's disease, with no federal contract revenue material to its $12.9B market cap. The company engages in extensive doctor payment programs, totaling $13.9M in 2024 across 98,411 payments.
12 months past · 3 months futureNBIX activity timeline
Executive Branch ConflictsNBIX held by Trump-administration officials
Lifetime Government AwardsNBIX federal contracts by year
Smart Money · 13F HoldingsHedge funds holding NBIX
Politicians Trading NBIXMembers of Congress with recent NBIX positions
Congressional TradesWho in Congress is trading NBIX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting NBIXLive legislation impacting this stock
Political ProfileWhere NBIX sits in Washington
[object Object]
STRUCTURAL: High regulatory density (85) due to healthcare sector and doctor payment volume ($13.9M in 2024), but no lobbying spend or donation patterns. EVIDENTIARY: Executive branch exposure shows Donald J. Trump holds $1,001-$15,000 in stock (get_executive_branch_exposure.by_ticker[0].holdings[1]), and one congressional trader (M001136) made purchase and sale transactions in June 2025. Net: Limited direct political engagement, with mixed but weak signals.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Increased scrutiny on doctor payments under Sunshine ActCMS"get_political_influence.doctor_payments shows $13.9M in 2024 across 98,411 payments, potentially drawing regulatory attention"
-
Drug pricing legislation impacting revenueCongress, HHS"Recent bill_impacts array shows 8 healthcare bills with estimated revenue impacts up to $6.06M"
Regulatory opportunities
-
Veterans Affairs contracts for drug supplyDepartment of Veterans Affairs"get_government_precedent.federal_contracts_summary shows 11 contracts totaling $6.65M obligation"
-
Potential favorable policy for neurological treatmentsFDA, Congress"Recent bill_impacts array includes multiple healthcare bills, some may be supportive"
Live signals + predictions for NBIX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades NBIX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord